Clinical trial
Multicenter, Open-label, Single-arm, Post-Marketing Clinical Study to Evaluate the Efficacy and Safety of Ravulizumab in Participants Clinically Diagnosed as Atypical Hemolytic Uremic Syndrome
NCT07308574 is registered in ClinicalTrials.gov with Alexion Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Multicenter, Open-label, Single-arm, Post-Marketing Clinical Study to Evaluate the Efficacy and Safety of Ravulizumab in Participants Clinically Diagnosed as Atypical Hemolytic Uremic Syndrome
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Phase
- Phase 4
- Overall status
- Recruiting
- Start date
- December 19, 2025
- Completion date
- June 25, 2027
- Enrollment
- 20 (estimated)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.